Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 23, 2026
AstraZeneca Deepens China Roots With Shanghai Cell Therapy Manufacturing Push
View original at finance.yahoo.comAstraZeneca Deepens China Roots With Shanghai Cell Therapy Manufacturing Push Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
AstraZeneca is the first multinational with end-to-end cell therapy manufacturing capability in China
60% confidenceThe company is committed to invest US$15 billion in China's biotech sector through 2030
60% confidence
Data points we hold from this source
| AstraZeneca AB · return 1year | 21.8 percent |
| AstraZeneca AB · return 1month | -9.0 percent |
| AstraZeneca AB · return 1week | -3.4 percent |
| AstraZeneca AB · return 3year | 33.2 percent |
| AstraZeneca AB · return 5year | 112.4 percent |
| AstraZeneca AB · return ytd | 2.2 percent |